NCT02632994

Brief Summary

This study is for patients who have participated in a previous study and who continue to receive benefit to have continued access to study drug and/or treatment.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Geographic Reach
1 country

3 active sites

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 15, 2015

Completed
2 days until next milestone

First Posted

Study publicly available on registry

December 17, 2015

Completed
Last Updated

September 29, 2025

Status Verified

September 1, 2025

First QC Date

December 15, 2015

Last Update Submit

September 26, 2025

Conditions

Interventions

Administered orally.

Administered orally.

Administered orally.

Administered orally.

Eligibility Criteria

Age18 Years+
Sexall
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • To be eligible patients must be currently receiving benefit in a concluded Lilly study for a compound that has opened an addendum in the continued access protocol.

You may not qualify if:

  • Patients must not be concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (3)

UCLA Medical Center

Torrance, California, 90505, United States

AVAILABLE

Fort Wayne Oncology & Hematology

Fort Wayne, Indiana, 46804, United States

AVAILABLE

Sarah Cannon Cancer Center

Nashville, Tennessee, 37203, United States

AVAILABLE

MeSH Terms

Conditions

Neoplasms

Interventions

LY3023414

Study Officials

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)

    Eli Lilly and Company

    STUDY DIRECTOR

Central Study Contacts

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or

CONTACT

Physicians interested in becoming principal investigators please contact

CONTACT

Study Design

Study Type
expanded access
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 15, 2015

First Posted

December 17, 2015

Last Updated

September 29, 2025

Record last verified: 2025-09

Locations